Cargando…

The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer

The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes p...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamczyk-Gruszka, Olga, Horecka-Lewitowicz, Agata, Strzelecka, Agnieszka, Wawszczak-Kasza, Monika, Gruszka, Jakub, Lewitowicz, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316851/
https://www.ncbi.nlm.nih.gov/pubmed/35885641
http://dx.doi.org/10.3390/diagnostics12071737
_version_ 1784754915338354688
author Adamczyk-Gruszka, Olga
Horecka-Lewitowicz, Agata
Strzelecka, Agnieszka
Wawszczak-Kasza, Monika
Gruszka, Jakub
Lewitowicz, Piotr
author_facet Adamczyk-Gruszka, Olga
Horecka-Lewitowicz, Agata
Strzelecka, Agnieszka
Wawszczak-Kasza, Monika
Gruszka, Jakub
Lewitowicz, Piotr
author_sort Adamczyk-Gruszka, Olga
collection PubMed
description The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes potentially involved in the genesis of endometrial cancer in the Polish population. One hundred and three white female patients with confirmed endometrial cancer were enrolled on the study. We performed sequencing using the Hot Spot Illumina panel and microsatellite stability with immunohistochemistry. We confirmed a key role of the TP53 mutation in progress to high-grade EC and parallelly some role of FGFR2 mutation. Moreover, our data present a vast landscape of mutations in EC and their polymorphism. We reported the meaning of FGFR2 mutation and TP53 (high copy number) in high-grade ECs. Our observation in MSI contribution is comparable with other studies. Finally, we see a strong need for the implementation of the TCGA classification.
format Online
Article
Text
id pubmed-9316851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93168512022-07-27 The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer Adamczyk-Gruszka, Olga Horecka-Lewitowicz, Agata Strzelecka, Agnieszka Wawszczak-Kasza, Monika Gruszka, Jakub Lewitowicz, Piotr Diagnostics (Basel) Article The morbidity and mortality caused by endometrial cancer (EC) is still rising worldwide. In recent years, a new system of tumor stratification has been proposed based on POLE-mutational status, TP53, and microsatellite stability status. The aim of the study was to analyze a vast panel on the genes potentially involved in the genesis of endometrial cancer in the Polish population. One hundred and three white female patients with confirmed endometrial cancer were enrolled on the study. We performed sequencing using the Hot Spot Illumina panel and microsatellite stability with immunohistochemistry. We confirmed a key role of the TP53 mutation in progress to high-grade EC and parallelly some role of FGFR2 mutation. Moreover, our data present a vast landscape of mutations in EC and their polymorphism. We reported the meaning of FGFR2 mutation and TP53 (high copy number) in high-grade ECs. Our observation in MSI contribution is comparable with other studies. Finally, we see a strong need for the implementation of the TCGA classification. MDPI 2022-07-18 /pmc/articles/PMC9316851/ /pubmed/35885641 http://dx.doi.org/10.3390/diagnostics12071737 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Adamczyk-Gruszka, Olga
Horecka-Lewitowicz, Agata
Strzelecka, Agnieszka
Wawszczak-Kasza, Monika
Gruszka, Jakub
Lewitowicz, Piotr
The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title_full The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title_fullStr The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title_full_unstemmed The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title_short The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
title_sort roles of tp53 and fgfr2 in progress made treating endometrial cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316851/
https://www.ncbi.nlm.nih.gov/pubmed/35885641
http://dx.doi.org/10.3390/diagnostics12071737
work_keys_str_mv AT adamczykgruszkaolga therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT horeckalewitowiczagata therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT strzeleckaagnieszka therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT wawszczakkaszamonika therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT gruszkajakub therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT lewitowiczpiotr therolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT adamczykgruszkaolga rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT horeckalewitowiczagata rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT strzeleckaagnieszka rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT wawszczakkaszamonika rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT gruszkajakub rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer
AT lewitowiczpiotr rolesoftp53andfgfr2inprogressmadetreatingendometrialcancer